Drug resistance characteristics of Mycobacterium tuberculosis isolates obtained between 2018 and 2020 in Sichuan, China. (28th January 2022)

• Record Type: Journal Article
• Authors: Zhou, Ruifeng; Zheng, Tianli; Luo, Dongxia; Zhu, Ma; Li, Qingfeng; Xu, Yuanhong; Wang, Dongmei; Luo, Jia; Zeng, Chongliang; Wei, Guo; Tang, Mingyuan; Zhao, Xing; Zhou, Mi; Zuo, Haojiang; Pei, Xiaofang
• Is Part Of: Epidemiology and infection. Volume 150(2022)
• Publication Date: 2022-01-28
• Subjects: Drug resistance -- GeneXpert MTB/RIF assay -- multidrug-resistant tuberculosis (MDR-TB) -- Mycobacterium tuberculosis; Communicable diseases -- Periodicals; Epidemiology -- Periodicals; 614.4
• DOI: 10.1017/S0950268822000127
• Languages: English
• ISSNs: 0950-2688

Abstract

Abstract: We investigated the drug resistance of Mycobacterium tuberculosis isolates from patients with tuberculosis (TB) and HIV, and those diagnosed with only TB in Sichuan, China. TB isolates were obtained from January 2018 to December 2020 and subjected to drug susceptibility testing (DST) to 11 anti-TB drugs and to GeneXpert MTB/RIF testing. The overall proportion of drug-resistant TB (DR-TB) isolates was 32.1% ( n = 10 946). HIV testing was not universally available for outpatient TB cases, only 29.5% (3227/10 946) cases had HIV testing results. The observed proportion of multidrug-resistant TB (MDR-TB) isolates was almost double than that of the national level, with approximately 1.5% and 0.1% of the isolates being extensively drug resistant and universally drug resistant, respectively. The proportions of resistant isolates were generally higher in 2018 and 2019 than in 2020. Furthermore, the sensitivities of GeneXpert during 2018–2020 demonstrated a downward trend (80.9, 95% confidence intervals (CI) 76.8–85.0; 80.2, 95% CI 76.4–84.1 and 75.4, 95% CI 70.7–80.2, respectively). Approximately 69.0% (7557/10 946) of the TB cases with DST results were subjected to GeneXpert detection. Overall, the DR-TB status and the use of GeneXpert in Sichuan have improved, but DR-TB challenges remain. HIV testing for all TB cases is recommended.